

Cardiology in the Young



Submit your paper online
<http://mc.manuscriptcentral.com/cty>

CAMBRIDGE
UNIVERSITY PRESS

Go Mobile

CJO Mobile (CJOm) is a streamlined
Cambridge Journals Online (CJO)
for smartphones and other
small mobile devices



- Use CJOm to access all journal content including *FirstView* articles which are published online ahead of print
- Access quickly and easily thanks to simplified design and low resolution images
- Register for content alerts or save searches and articles – they will be available on both CJO and CJOm
- Your device will be detected and automatically directed to CJOm via: journals.cambridge.org



CAMBRIDGE
UNIVERSITY PRESS

Cardiology in the Young

journals.cambridge.org/CTY

Editor-in-Chief

Professor Edward J. Baker

Oxford Radcliffe Hospitals NHS Trust, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, UK

Emeritus Founding Editor

Professor Robert H. Anderson

Cardiac Unit, Institute of Child Health, University College London,
30 Guilford Street, London WC1N 1EH, UK

Associate Editors

Allen D. Everett, Baltimore, MD

Jeffrey P. Jacobs, St Petersburg, FL

International Editors

G. William Henry, Chapel Hill, NC

Hiromi Kurosawa, Tokyo

Supplements Editor Jeffrey P. Jacobs, St Petersburg, FL

Images Editor Roxane McKay, Memphis, TN

Founding Editors

Anton E. Becker, Amsterdam; Giancarlo Crupi, Bergamo; Arthur Garson Jr, Charlottesville, VA; Fernando Lucchese, Porto Alegre; Lucio Parenzan, Bergamo; the late Atsuyoshi Takao, Tokyo; Michael Tynan, London

International Editorial Board

Lindsey D. Allan (London)
Maurice Beghetti (Geneva)
Lee N. Benson (Toronto)
Per G. Bjørnstad (Oslo)
Anthony C. Chang (Orange, CA)
Tjark Ebels (Groningen)
Timothy Feltes (Columbus, OH)
J. William Gaynor (Philadelphia, PA)
Allan Goldman (London)
Willem A. Helbing (Rotterdam)
John Hess (Munich)
Eero Jokinen (Helsinki)
Tom Karl (Brisbane)
Doff B. McElhinney (Boston, MA)

Luc Mertens (Toronto)
Cleonice de C. Mota (Belo Horizonte)
Jane Newburger (Boston, MA)
Edgardo E. Ortiz (Quezon City)
Daniel Penny (Melbourne)
Andrew N. Redington (Toronto)
Girish S. Shirali (Charleston, SC)
Norman H. Silverman (Palo Alto, CA)
Giovanni Stellin (Padova)
András Szatmári (Budapest)
Hideki Uemura (London)
Steven A. Webber (Pittsburgh, PA)
James L. Wilkinson (Melbourne)
Shi-Joon Yoo (Toronto)

Cardiology in the Young is indexed and abstracted in Index Medicus/MEDLINE; Current Contents/Clinical Medicine; Research Alert; Sci Search; EMBASE/Excerpta Medica

Commissioning Editor: Dan Edwards
Production Editor: Nicki Marshall

Design and Production: MPS Limited, Bangalore
Printed & Bound: Latimer Trend, Plymouth

Published by Cambridge University Press (Journals), Edinburgh Building, Shaftesbury Road, Cambridge CB2 8RU, UK
Tel: +44 (0)1223 326491; Fax: +44 (0)1223 325802; E-mail: dedwards@cambridge.org

Cambridge Journals Online

For further information about this journal please
go to the journal website at:

journals.cambridge.org/CTY



CAMBRIDGE
UNIVERSITY PRESS

PAH

The first and only PDE-5 inhibitor

REVATIO® 20mg tablets (sildenafil) ABBREVIATED PRESCRIBING INFORMATION

Please refer to the SmPC before prescribing Revatio 20mg Tablets.

Presentation: White, round, biconvex film-coated tablets marked "PFIZER" on one side and "RVT 20" on the other containing 20mg of sildenafil as the citrate. **Indications:** Treatment of adult patients with pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. Treatment of paediatric patients aged 1 to 17 years old with PAH. Efficacy in improvement in exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease. **Dosage:** For oral use. Treatment should only be initiated and monitored by a physician experienced in the treatment of PAH. In case of clinical deterioration in spite of Revatio treatment, alternative therapies should be considered. **Adults:** 20mg taken three times a day with or without food. **Elderly:** Dosage adjustments not required. **Paediatric Population:** For patients aged 1 to 17 years old ≤ 20 kg the recommended dose is 10 mg (1 ml of compounded solution) three times a day, and for patients ≥ 20 kg is 20mg (2ml of compounded solution or 1 tablet) three times a day. For instructions on compounding of the medicinal product please refer to the SmPC. **Renal impairment:** Initial dosage adjustments not required. If therapy is not well tolerated consider adjusting dose to 20mg twice daily. **Hepatic impairment (Child-Pugh class A and B):** Initial dose adjustments not required. If therapy is not well tolerated consider adjusting dose to 20 mg twice daily. **Severely impaired hepatic function (Child-Pugh class C):** Revatio is contraindicated in patients with severe hepatic impairment, see Contraindications. **Children and adolescents:** The safety and efficacy of Revatio in children below 1 year of age has not been established. **Discontinuation of treatment:** Limited data suggest abrupt discontinuation of Revatio is not associated with rebound worsening of PAH. To avoid the possibility of clinical deterioration a gradual dose reduction should be considered. Intensified monitoring is recommended during this period. *Use in patients using other medicines:*

Any dose adjustment should be administered only after a careful benefit-risk assessment. For use with CYP3A4 inhibitors like erythromycin or saquinavir consider adjusting dose to 20mg twice daily. For use with more potent CYP3A4 inhibitors like clarithromycin, telithromycin and nefazodone, consider adjusting dose to 20mg once daily. Dose adjustments of Revatio may be required with CYP3A4 inducers (see Drug Interactions). **Contraindications:** Hypersensitivity to Revatio or to any of the excipients. Co-administration with nitric oxide donors (such as amyl nitrite) or nitrates in any form due to hypotensive effects (see pharmacodynamic properties). Combination with the most potent of the CYP3A4 inhibitors e.g. ketoconazole, itraconazole, ritonavir (see Drug Interactions). Patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION) (see special warnings). Severe hepatic impairment; recent stroke or myocardial infarction; severe hypotension at initiation. **Warnings and Precautions:** Efficacy not established in patients with functional class IV PAH. Risk-benefit balance of Revatio not established in functional class I PAH. Studies have been performed in forms of PAH related to primary (idiopathic), connective tissue disease or congenital heart disease. Use not recommended in other forms of PAH. Use not recommended in patients with known hereditary degenerative retinal disorders e.g. retinitis pigmentosa. Susceptible patients could be adversely affected by mild to moderate vasodilatory effects of Revatio. Sildenafil potentiates the hypotensive effect of nitrates (see Contraindications). Caution advised in patients with anatomical deformation of the penis or predisposed to priapism. Visual defects and cases of non-arteritic anterior ischaemic optic neuropathy have been reported in connection with the intake of sildenafil and other PDE5 inhibitors. Caution is advised when sildenafil is administered with an alpha-blocker, symptomatic hypotension may develop in susceptible patients (see Drug Interactions). Patients should be hemodynamically stable on alpha-blocker therapy prior to initiating sildenafil. Administration to patients with bleeding disorders or active peptic ulceration only after careful benefit-risk assessment. Increased risk for bleeding when sildenafil is initiated in PAH patients already using a Vitamin K antagonist, particularly in patients with PAH secondary to connective tissue disease. No data are available with sildenafil in patients with pulmonary hypertension associated with veno-occlusive disease. In these patients life-

therapy while they grow



approved for children with PAH

Revatio[®] 
sildenafil citrate

threatening pulmonary oedema has been reported with use of other vasodilators. Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take Revatio. **Drug Interactions:** Revatio tablets is principally metabolised by the CYP P450 isoforms 3A4 and 2C9. Co-administration of Revatio is not advised with potent P450 inhibitors (see Contraindications). A lower starting dose of Revatio should be considered in patients taking CYP3A4 inhibitors (see Warnings and Precautions). Co-administration of bosentan (a moderate inducer of CYP3A4, CYP2C9 and possibly of CYP2C19) 125mg twice daily with Revatio tablets 80 mg three times a day (at steady state) resulted in a 63% decrease of Revatio AUC and a 50% increase in bosentan AUC. Caution is recommended. Revatio potentiates the hypotensive effect of nitrates (see Contraindications). Nicorandil, amlodipine and alpha-blockers in combination with Revatio have the potential to drop blood pressure in susceptible patients (see Warnings and Precautions). No significant interactions have been observed between Revatio and warfarin or acenocoumarol. For other Drug Interactions please refer to the SmPC. Paediatric population: Interaction studies have only been performed in adults. **Pregnancy and lactation:** Due to lack of data Revatio should not be used in pregnant women unless also using appropriate contraceptive measures. Revatio should not be administered to breast-feeding mothers. **Driving and operating machinery:** Caution if affected by dizziness or altered vision. **Side-Effects:** Clinical study experience: The most commonly reported side-effects were headache, flushing, dyspepsia, back pain, diarrhoea and limb pain. Other side-effects reported were as follows: Myalgia, cough, epistaxis, insomnia, pyrexia, influenza, visual disturbance not otherwise specified (NOS), anaemia, vertigo, abnormal sensation in eye, chromatopsia, cyanopsia, diplopia, eye irritation, blood shot eyes/red eyes, photophobia, retinal haemorrhage, visual acuity reduced, abdominal distension, gastritis, gastroenteritis, gastroesophageal reflux disease, haemorrhoids, sinusitis, nasal congestion, dry mouth, cellulitis, weight increased, fluid retention, paraesthesia, tremor, burning sensation, migraine, hypoaesthesia, anxiety, bronchitis, rhinitis, gynaecomastia, alopecia, erythema, night sweats. In postmarketing surveillance, the adverse event/reactions that have been reported with an unknown frequency are skin rash, hypotension, priapism and sudden deafness.

In the treatment of male erectile dysfunction adverse events/reactions reported include: Eye disorders: Non-arteritic anterior ischemic optic neuropathy (NAION), retinal vascular occlusion and visual field defect. Paediatric Population: In a paediatric study over 16 weeks, side effects were generally consistent with that in adults, the most common reported were: vomiting, cough, pyrexia, nausea, abdominal pain, photobia, and spontaneous penile erections in male patients. In a long term extension study at 2.2 years the most commonly reported adverse events were headache, erection increased, vomiting, abdominal pain, cough and dyspepsia. Over the first two years of the study, 4 of 229 subjects had a serious event: these were convulsion, hypersensitivity, hypoxia and ventricular arrhythmia. **Overdose:** Standard supportive measures to be adopted as required. **Legal category:** POM. **Basic NHS cost:** Packs of 90, 20mg tablets (EU/1/05/318/001) £373.50. Marketing Authorisation Holder: Pfizer Limited, Sandwich, Kent, CT13 9NJ, United Kingdom. Further information on request: Pfizer Limited, Walton Oaks, Dorking Road, Tadworth, Surrey KT20 7NS Last revised: 05/2011. Ref: RV11_0

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk Adverse events should also be reported to Pfizer Medical Information on +44 (0)1304 616161

Date of preparation: June 2011 EUPV0453a



Cardiology in the Young

COPYRIGHT © 2011 CAMBRIDGE UNIVERSITY PRESS
ISSN 1047-9511

Table of Contents December 2011

ORIGINAL ARTICLES

Physical activity and obesity in children with congenital cardiac disease <i>Trenda D. Ray, Angela Green, Karen Henry</i>	603
Serum and pulmonary vascular endothelial growth factor/receptors and haemodynamic measurements in cyanotic congenital heart disease with decreased pulmonary blood flow <i>İlknur Tolunay, Sedef Tunaoglu, Nalan Akyürek, Velit Halid, Rana Olgunturk, Serdar Kula</i>	608
Cardiac computed tomography and conventional angiography in the diagnosis of congenital cardiac disease in children: recent trends and radiation doses <i>Guy G. Gberardi, Gareth R. Iball, Michael J. Darby, John D.R. Thomson</i>	616
Veno-venous bridges: the forerunners of the sinus venosus defect <i>Ryan J. Butts, Andrew M. Crean, Anthony M. Hlavacek, Diane E. Spicer, Andrew C. Cook, Erwin N. Oechslin, Robert H. Anderson</i>	623
Comparative efficacy of sildenafil in Eisenmenger's syndrome secondary to atrial septal defect versus ventricular septal defect: a cardiac catheterisation follow-up study <i>Naveen Garg, Nishant Tripathy, Nakul Sinha</i>	631
Adult congenital cardiac surgery in Indonesia <i>Karina V. Wilamarta, Yoga Yuniadi, Jusuf Rachmat, Dicky Fakhri, Tarmizi Hakim, Maizul Anwar</i>	639
Lessons from inter-stage cardiac magnetic resonance imaging in predicting survival for patients with hypoplastic left heart syndrome <i>Marina L. Hughes, Victor T. Tsang, Martin Kostolny, Alessandro Giardini, Vivek Muthurangu, Andrew M. Taylor, Katherine Brown</i>	646
Design and rationale of a genetic cohort study on congenital cardiac disease: experiences from a multi-institutional platform in Quebec <i>Marie-Pierre Dubé, Jean-Luc Bigras, Maryse Thibeault, Nathalie Bureau, Philippe Chetaille, Andrea Richter, Jocelyne Mercier, Marc Bellavance, Charles Roblicek, Rima Rozen, Mona Nemer, Paul Khairy, Roxanne Gendron, Gregor Andelfinger</i>	654
Fontan conversion with concomitant arrhythmia surgery for the failing atriopulmonary connections: mid-term results from a single centre <i>Anuradha Sridhar, Alessandro Giamberti, Sara Foresti, Riccardo Cappato, Carlos Rubio-Iglesias García, Nerea Delgado Cabrera, Angelo Micheletti, Diana Negura, Claudio Bussadori, Gianfranco Butera, Alessandro Frigiola, Mario Carminati, Massimo Chessa</i>	665
Quality of life of patients with congenital heart diseases <i>Ana M. Silva, Cláudia Vaz, Maria E. G. Areias, Daniela Vieira, Cidália Proença, Victor Viana, Cláudia Moura, José C. Areias</i>	670
Comparison of right ventricular deformation and dyssynchrony in patients with different subtypes of hypoplastic left heart syndrome after Fontan surgery using two-dimensional speckle tracking <i>Colin Petko, Inga Voges, Jana Schlangen, Jens Scheewe, Hans-Heiner Kramer, Anselm S. Uebing</i>	677
Can RoTEM [®] analysis be applied for haemostatic monitoring in paediatric congenital heart surgery? <i>Jo Bønding Andreasen, Anne-Mette Hvas, Kirsten Christiansen, Hanne Berg Ravn</i>	684

Table of Contents *continued*

IMAGES IN CONGENITAL CARDIAC DISEASE

- Pentalogy of Cantrell demonstrated by computed tomography in an infant 692
Nasroolla Damry, Sanjiva Patber, Sophie M. Milani
- Tetralogy of Fallot with double aortic arch 695
Andrew Robert Harper, Monica Dai, Rashmi M. Prabhatba

BRIEF REPORTS

- Congenital giant aneurysm of the left atrial appendage in an infant 697
Anil Bhattarai, Massimo A. Padalino, Giovanni Stellin
- Left cervical aortic arch associated with multiple vascular anomalies 700
José Luiz Baltazar Jacob
- Modified Nikaidoh procedure in a patient with transposition of the great arteries, ventricular septal defect, and left ventricular outflow tract obstruction with unusual coronary anatomy 703
Murat Ugurlucan, Omer A. Sayin, Emin Tireli
- Danon disease: characteristic late gadolinium enhancement pattern on cardiac magnetic resonance imaging 707
Bharat S. Dara, Paolo G. Rusconi, Joel E. Fishman
- Systemic arterial supply of the right lung with venous drainage to the pulmonary arterial circuit 710
Peter Fritsch, Freyja-Maria Smolle-Juettner, Andreas Gamillscheg
- Silent rupture of sinus of Valsalva aneurysm: a refutation of the Okham's razor principle 713
Joseph Dayan, Suvo Sett, Usha Krishnan

LETTERS TO THE EDITOR

- Heart rate variability during nap sleep 716
Tomoyuki Kawada
- Three-dimensional echocardiographic assessment of rhabdomyoma in a newborn: the merit of three dimension over two dimension 718
Daisuke Matsubara, Shigeaki Matsubara

AEPC NEWSLETTER

- Association for European Paediatric Cardiology Newsletter 719
Katarina Hanséus

This journal issue has been printed on FSC-certified paper and cover board. FSC is an independent, non-governmental, not-for-profit organization established to promote the responsible management of the world's forests. Please see www.fsc.org for information

Cardiology in the Young © 2011 Cambridge University Press, ISSN 1047-9511 is published bi-monthly

Subscription information: Volume 21 (6 issues) will appear in 2011. Correspondence concerning subscriptions should be addressed to: Journals Customer Services, Cambridge University Press, The Edinburgh Building, Cambridge CB2 8RU, UK. Tel: +44 (0)1223 326070; Fax: +44 (0)1223 325150; E-mail enquiries: journals_subscriptions@cambridge.org; Web: www.cambridge.org; Cambridge Journals Online: www.journals.cambridge.org. The subscription rate for 2011 Volume 21 (6 issues) is: Individual rate £350 or US\$600; Institutional rate £704 or US\$1218. All prices inclusive of postage. Cheques should be made payable to Cambridge University Press. Copyright: The submission of a manuscript implies the following: (a) that the work described has not been published before, except in the form of an abstract or as part of a published lecture, review, or thesis; (b) that it is not under consideration for publication elsewhere; (c) that all co-authors approve its publication; (d) that its publication is approved by the responsible authorities at the institute where the work has been carried out; (e) that when the manuscript is accepted for publication, the authors agree to the automatic transfer of the copyright to the publisher; (f) that the manuscript will not be published elsewhere in any language without the consent of the copyright holders, and (g) that written permission of the copyright holder is obtained by the authors for material used from other copyrighted sources. All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in video disks, etc., without first obtaining written permission from the publishers. The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations. While the advice and information in this journal are believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Cambridge University Press publishes advertisements in this journal while relying on the responsibility of the advertiser to comply with all legal requirements relating to the marketing and sale of products or services advertised. Cambridge University Press and the editors are not responsible for claims made in the advertisements published in the journal. The appearance of advertisements in Cambridge University Press publications does not constitute endorsement, implied or intended, of the product advertised or the claims made for it by the advertiser. Photocopies may not be made for personal or in-house use beyond the limitations stipulated under US Copyright Law. Advertisements: For advertisement rates and information on advertisement copy contact *Cardiology in the Young*, Advertising Dept., Cambridge University Press (Journals), Edinburgh Building, Shaftesbury Road, Cambridge CB2 8RU, UK. Tel: +44 (0)1223 325083; Fax: +44 (0)1223 325801; E-mail: ad_sales@cambridge.org. Change of address: Please notify the Subscription Department. Send new address and postal code, and the address label from a current issue to Journals Customer Services, Cambridge University Press, FREEPOST CB27, The Edinburgh Building, Cambridge CB2 8BR, UK. Tel: +44 (0)1223 326070; Fax: +44 (0)1223 325150; E-mail enquiries: journals_subscriptions@cambridge.org; Web: www.cambridge.org; Cambridge Journals Online: www.journals.cambridge.org. Printing: *Cardiology in the Young* (ISSN 1047-9511) is printed bi-monthly in 2011 by Latimer Trend, Plymouth.

CARDIOLOGY IN THE YOUNG

Submission to *Cardiology in the Young* is exclusively via the web-based peer-review system, CTY Manuscript Central.

Online submission enables rapid review and allows online manuscript tracking.

We invite all authors to submit online any NEW MANUSCRIPTS that are to be considered for publication in *Cardiology in the Young*.

Please use the following URL: <http://mc.manuscriptcentral.com/cty>

Editorial policies

Cardiology in the Young is devoted to cardiovascular issues affecting the young and the older patient with the sequels of cardiac disease acquired in childhood. Submission of both basic research and clinical papers is encouraged. Articles on fundamental principles will also be considered for publication. Reviews on recent developments are welcome. The Journal serves the interest of all professionals concerned with these topics. By design, the Journal is international and multidisciplinary in its approach, and the members of the Editorial Board take an active role in the Journal's mission. Prospective authors are encouraged to consult with the editors and members of the Editorial Board with any inquiries. The editors encourage the submission of articles from developing countries.

Articles should be concerned with original research not published previously and not being considered for publication elsewhere. Submission of a manuscript to the Journal gives the publisher the right to publish that paper if it is accepted, and the copyright of the manuscript becomes property of the publisher. Manuscripts may be edited to improve clarity and expression.

Authors must ensure that their studies comply with appropriate institutional and national guidelines for ethical matters. Specifically, by submission of a manuscript, the authors are responsible for compliance with guidelines and regulations of the authors' institution and all appropriate governmental agencies.

Articles including human subjects must include a statement that informed consent was obtained and that the study was reviewed and approved by the institution's committee on human experimentation. Articles including animal experimentation must conform to the principles of the American Physiological Society, and a statement acknowledging conformation to these standards must be included in the *Materials and methods* section of the manuscript. Authors are also requested to identify possible conflicts of interest, especially as it relates to commercial sponsorship or equity holdings.

Language

The language of the Journal is English, but acceptance of a manuscript will reflect scientific rather than grammatical content. The editors undertake to facilitate the publication of papers from those authors whose native language is not English.

Manuscripts

Manuscripts should be submitted via the web-based peer-review system, CTY Manuscript Central and must include a complete set of Figures. Further information regarding Figure formats is outlined below. Type all pages with double-spacing and wide margins on all pages, with left justified margins. Divide the manuscript into the following sections: Title Page, Abstract, Keywords (3–6), Introduction, Materials and methods, Results, Discussion, Acknowledgements, References, Tables, Figure legends and Figures.

Cover letter

A submission letter is required for all papers. A submission letter template will be attached to the confirmation email that the author will receive after completing online submission.

Authorship

Authorship should be assumed only by those workers who have contributed materially to the work and its report, and who accept the responsibility for the accuracy of the concepts expressed. Colleagues who have otherwise assisted or collaborated should be recognized in the section for acknowledgements. An excellent guide to authorship is given by the Style Manual Committee of the Council of Biology Editors, and the editors encourage consultation with this source.

Style

The Journal uses the English language, it does not use Latin terms such as 'superior vena cava'. Anatomic terms should be given in the English language. Do not use abbreviations or symbols. *Submissions including Latin terms, abbreviations or symbols will be returned to the corresponding author for correction before they can be accepted for peer review.* Headlines and subheadings should be liberally employed in the methods, results, and discussion sections. Use short paragraphs whenever possible. The authors should strive for clarity of expression, avoiding, in particular, the use of jargon. Authors should also avoid conventions such as

Group 1, Group 2, and so on, using descriptive titles rather than alphanumeric codes.

Title page

Follow the on-screen instruction on CTY Manuscript Central to enter each piece. The title page should include a descriptive title, a running head title not to exceed 50 characters (and with no abbreviations), authors' complete names (first names and initials followed by family name), academic addresses, corresponding author (with full address, telephone and fax numbers, and email address), keywords (3–6 for indexing purposes and words not used in main title of article), and all sources of financial support, including grants from non-profit organizations and/or any commercial support. Please note that author qualifications should not be included on the authors list on the title page.

Abstract

The Abstract should be no more than 250 words and should include statements identifying relevant methods and results justifying publication. Do not use abbreviations or symbols.

Introduction

The Introduction should be brief and set out the purposes for which the study has been performed. It should not include an extensive review of the literature.

Materials and methods

The Materials and methods should be sufficiently detailed so that readers and reviewers can understand precisely what has been done without studying the references directly. The description may be abbreviated when well-accepted techniques are used with appropriate reference to previously published methods. Statements confirming conformation to institutional and governmental review of the experimental protocol (see above in the Editorial policies section) should be included here.

Results

The results should be presented precisely. Reference to Tables and Figures, to the extent that they contribute substantively to help the reader understand clearly the relevant positive and negative findings, is encouraged.

Keep discussion of their importance to a minimum in this section of the manuscript.

Discussion

The Discussion should relate directly to the study being reported. The Discussion should interpret the

results, should describe the relevance of the results, and should include a discussion of the limitations of the study. Do not include a general review of the topic.

Acknowledgements

Acknowledgements should follow the discussion.

References

References should be numbered consecutively (in superscript) as they appear in the text. Type the reference list with double-spacing on a separate sheet. References (using Index Medicus abbreviations) should appear in the style as demonstrated below. Please note that if more than six authors, the **first three** authors should be listed and then 'et al.'. Examples:

1. Redington AN, Rigby ML, Oldershaw P, Gibson DG, Shinebourne EA. Right ventricular function 10 years after the Mustard operation for transposition of the great arteries: analysis of size, shape, and wall motion. *Br Heart J* 1989; 62: 455–461.
2. Smith VR, Jones AL, Miller W et al. Left ventricular myocardial velocities in children. *Eur Heart J* 2000; 21: 104–112.
3. Zuberbuhler JR. *Clinical Diagnosis in Pediatric Cardiology*. Churchill Livingstone, New York, 1981.
4. Frantz EG. Adult respiratory distress syndrome in children. In: Harried HS, Jr (ed.) *Pediatric Pulmonary Heart Disease*. Little, Brown, Boston, 1990, pp 315–324.

Tables

Tables should follow the style as demonstrated in issues to date, and be essential to the understanding of the text. Tables should have short descriptive titles and should be numbered (1, 2, 3 etc.) as they appear sequentially in the text. If only one Table is included, it should be referred to as Table. Submit each Table on a separate sheet of paper. All abbreviations and symbols should be defined in a footnote below the Table.

Figures

Authors are not charged for colour printing costs.

Please ensure that all graphs are exclusively submitted as 2-dimensional images.

To ensure that your figures are reproduced to the highest possible standards, Cambridge Journals recommends the following formats and resolutions for supplying electronic figures.

Please ensure that your figures are saved at final publication size and are in our recommended file formats. Following these guidelines will result in high quality images being reproduced in both the print and the online versions of the journal.

Line artwork

Format: tif or eps

Colour mode: black and white (also known as 1-bit)

Resolution: 1200 dpi

Combination artwork (line/tone)

Format: tif or eps

Colour mode: grayscale (also known as 8-bit)

Resolution: 800 dpi

Black and white halftone artwork

Format: tif

Colour mode: grayscale (also known as 8-bit)

Resolution: 300 dpi

Colour halftone artwork

Format: tif

Colour mode: CMYK colour

Resolution: 300 dpi

If you require any further guidance on creating suitable electronic figures, please visit http://dx.sheridan.com/guidelines/digital_art.html. Here you will find extensive guidelines on preparing electronic figures and also have access to an online pre-flighting tool (<http://dx.sheridan.com/index.html>) where you can check if your figures are suitable for reproduction.

Supplementary On-line Material

The online platform gives authors the opportunity to include data that would be impossible or impractical to include in the printed version. These data might substantially enhance the importance of the research and might also be of benefit to readers. Authors may include tables and figures as well as data such as videos, 3-D structures/images, extensive datasets and any other supplementary material not suitable for print duplication. All supplementary material must be submitted with the original manuscript. Supplementary data should be referred to in the text with the prefix "S" (e.g. Supplementary Table S1, Supplementary Figure S1). Supplementary files will not be copy-edited, and will be published as supplied.

Case Reports/Brief Reports

Case Reports which add important new information will be published as Brief Reports. Articles published in this section should have no more than three authors, 1,000 words, an abstract (of about 60 words), 3–6 key words, two Figures or Tables, and 10 references.

Editorials and Letters to the Editor

Readers are encouraged to write about any topic that relates to cardiology in the young. Such letters will appear in *Letters to the Editor*. They should be no longer than 500 words. Editorials are written on invitation but unsolicited articles of approximately

1,500 words which may have particular topical interest will be welcomed for consideration.

Reviews

Reviews of recent developments are welcome. Authors are encouraged to contact the editor to determine the appropriateness for inclusion.

Images in Congenital Cardiac Disease

Definitive, unique, or extraordinary pictures of any aspect of congenital cardiac disease will be presented with an accompanying legend of not more than 250 words (one double-spaced page). A maximum of three authors and one reference may be included. Instructional value and artistic merit will be considered in addition to scientific import and clinical relevance. Authors will not be charged colour printing costs.

Offprints

Article offprint order forms will be sent to the corresponding author with the proofs. If you do not receive the relevant form please email the Production Editor at: nmarshall@cambridge.org

Reprints

Article reprints (following publication) are available from special_sales@cambridge.org. A minimum reprint order of 500 copies is required.

Permission

Requests for permission to reproduce any material originally published in *Cardiology in the Young* should be sent to the Permissions Manager at lnicol@cambridge.org

Announcements

Meetings and courses will be announced in each Issue. Refer to the Announcements Section for appropriate guidelines. Please email details to: ctyedoffice@cambridge.org The Journals homepage, www.journals.cambridge.org/cty, offers paying advertisers the opportunity to promote conferences/courses and recruitment vacancies (subject to editorial approval). For rate details please email: ad-sales@cambridge.org

Page changes

Page changes will not be made once proofs are prepared for publication.

Articles not conforming to these instructions will be returned to the corresponding author for correction, and will delay review and publication.

(Revised January 2011)